Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Ruben A. Mesa, Andrew C. Perkins, Yeow Tee Goh, Maria Laura Fox, Donal P McLornan, Jeanne Palmer, Lynda Foltz, Alessandro Maria Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung-Eun Lee, Jun Kawashima, Bryan Strouse, Francisco Gonzalez Carreras, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2023-177774

Published: 2023

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro

Blood (2023) 142 (Supplement 1): 868.

https://doi.org/10.1182/blood-2023-189270

Published: 2023

Journal Articles

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Blood (2023) 142 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2023-184423

Published: 2023

Journal Articles

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Chandramouli Nagarajan, Melinda Tan, Yunxin Chen, Melissa Ooi, Sanjay De Mel, Allison Tso, Lawrence Ng, Hein Than, Yeow Tee Goh, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 6721.

https://doi.org/10.1182/blood-2023-173476

Published: 2023

Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Blood (2022) 140 (Supplement 1): 1514–1517.

https://doi.org/10.1182/blood-2022-162783

Published: 2022

Journal Articles

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Morag Griffin, Richard Kelly, Dries Deeren, Yeow Tee Goh, Eric Tse, Kensuke Usuki, Raymond Wong, Regina Horneff, Lisa Tan, Michael Yeh, Jessica Savage, Jeff Szer

Blood (2022) 140 (Supplement 1): 2937–2939.

https://doi.org/10.1182/blood-2022-163117

Published: 2022

Journal Articles

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Allison Ching Yee Tso, Wee Joo Chng, Yeow Tee Goh, Melissa Ooi, Yunxin Chen, Chandramouli Nagarajan, Daryl Tan, Kiat Hoe Ong

Blood (2022) 140 (Supplement 1): 12596–12597.

https://doi.org/10.1182/blood-2022-157940

Published: 2022

Journal Articles

Differential Activation of V γ 4V δ 1 and V γ 9V δ 2 Cord Blood Derived Gamma Delta T Cells upon Exposure to EBV-Lcl and K562 Cells

Jeremy Wee Kiat Ng, Joey Lai, Tony Kiat Hon Lim, William YK Hwang, Shang Li, Connie J. Eaves, Yeow Tee Goh, Alice Cheung

Blood (2021) 138 (Supplement 1): 2790.

https://doi.org/10.1182/blood-2021-152151

Published: 2021

Journal Articles

Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

Raymond S Wong, Juan Ramon Navarro, Narcisa Sonia Comia, Yeow Tee Goh, Henry Idrobo, Daolada Kongkabpan, David Gomez-Almaguer, Mohammed Al-Adhami, Temitayo Ajayi, Paulo Alvarenga, Pascal Deschatelets, Cedric Francois, Federico Grossi, Teresita Dumagay

Blood (2021) 138 (Supplement 1): 606.

https://doi.org/10.1182/blood-2021-147493

Published: 2021

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies - 15-Year Follow-up of Multicenter Study in Singapore

Qianhuang Ian Q Wu, MBBS, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, Michelle Poon, MBBS, MRCP, FRCPATH, Lip Kun Tan, MBBS, FRCP, FRCPath, Yang Liang Boo, MD, Yeow Tee Goh, MBBS, Aloysius YL Ho, MBBS,FRCP,FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141581

Published: 2020

Journal Articles

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Colin Phipps, MD, Chandramouli Nagarajan, MBBS, Lawrence Ng, MBBS, Jane L Chua, Yunxin Chen, MBBS, Shin Yeu Ong, MD, Melinda Si Yun Tan, MBBS, Nicholas Francis Grigoropoulos, MD PhD, Sathish Gopalakrishnan, MD, Heng Joo Ng, MBBS, William YK Hwang, MBBS, Yeow Tee Goh, MBBS, Yuh Shan Lee, MBBS

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-142275

Published: 2020

Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Blood (2020) 136 (Supplement 1): 47–50.

https://doi.org/10.1182/blood-2020-139677

Published: 2020

Journal Articles

Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells

Kar Wai Tan, PhD, Zhihui Li, Joey Lai, Dianyan Guo, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, Shang Li, MD PhD, Connie J. Eaves, PhD, Yeow Tee Goh, MBBS, Alice Cheung, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-140667

Published: 2020

Journal Articles

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-135880

Published: 2020

Journal Articles

Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas

Yunxin Chen, MBBS, Chandramouli Nagarajan, Nicholas Francis Grigoropoulos, Shin-Yeu Ong, MD, Kit Yan Loh, Allan Zhi Kai Goh, Yeow Tee Goh, MBBS, MD, Yuh Shan Lee, FRCPath, MRCP, MBBS

Blood (2018) 132 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2018-99-112732

Published: 2018

Journal Articles

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Hironobu Minami, MD PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS,MD, Philipp le Coutre, MD, Michael W. Deininger, MD PhD, Gabriel Etienne, MD PhD, Manu Sondhi, MD PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD, Michael J. Mauro, MD

Blood (2018) 132 (Supplement 1): 792.

https://doi.org/10.1182/blood-2018-99-113609

Published: 2018

Journal Articles

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Blood (2018) 132 (Supplement 1): 5637.

https://doi.org/10.1182/blood-2018-99-116844

Published: 2018

Journal Articles

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Blood (2018) 132 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2018-99-118364

Published: 2018

NARROW

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Differential Activation of V γ 4V δ 1 and V γ 9V δ 2 Cord Blood Derived Gamma Delta T Cells upon Exposure to EBV-Lcl and K562 Cells

Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies - 15-Year Follow-up of Multicenter Study in Singapore

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only